The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Aytu BioPharma's quick ratio for the quarter that ended in Mar. 2024 was 0.69.
Aytu BioPharma has a quick ratio of 0.69. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Aytu BioPharma's Quick Ratio or its related term are showing as below:
STU:AY20'
s Quick Ratio Range Over the Past 10 Years
Min: 0.04 Med: 1 Max: 6.08
Current: 0.69
During the past 13 years, Aytu BioPharma's highest Quick Ratio was 6.08. The lowest was 0.04. And the median was 1.00.
STU:AY20's Quick Ratio is ranked worse than 75.47% of 1072
companies
in the Drug Manufacturers industry
Industry Median: 1.32
vs STU:AY20: 0.69
Aytu BioPharma Quick Ratio Historical Data
The historical data trend for Aytu BioPharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aytu BioPharma's Quick Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma's Quick Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's Quick Ratio falls into.
Aytu BioPharma Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Aytu BioPharma's Quick Ratio for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma (STU:AY20) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Aytu BioPharma Quick Ratio Related Terms
Thank you for viewing the detailed overview of Aytu BioPharma's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:AY20 has been successfully added to your 